Vireo 10-Q: Q3 Revenue $253.7M, Net Loss $24.0M, Debt Nearly Doubles to $293M
VREOF is trading near its 52-week low of $6.4 (5.6% above the low).
Summary
Vireo's Q3 10-Q confirms $253.7M revenue but a $24.0M net loss driven by $34.8M of current tax expense, with long-term debt up to $293.0M and cash down to $88.8M. It also details the post-quarter $60.0M Needham refinancing and the November 9 Fluent acquisition close.
Key Events · Earnings and Guidance · VREOF
-
Q3 Revenue $253.7M, Net Loss $24.0M
Revenue rose 177% to $253.7M from $91.7M, but net loss was $24.0M as current income tax expense of $34.8M exceeded $4.0M of pre-tax income.
-
Debt Nearly Doubles, Cash Falls
Total long-term debt reached $293.0M at September 30, 2026 versus $143.9M at December 31, 2025, while cash dropped to $88.8M from $102.2M.
-
Non-Cannabis Segment at 13% Margin
Hawthorne and Bridgewell contributed $55.6M of Q3 revenue but only $7.4M of gross profit, a 13% margin versus 51% for cannabis.
-
Needham Loan Refinances 15% Seller Note
On October 2, 2026 the company closed a $60.0M Needham Bank term loan at 8.50% fixed, replacing the $49.0M IIP seller note and adding $11.0M of principal.
Analysis · VREOF · Life Sciences
The headline numbers were already out in the November 10 8-K, but the full 10-Q shows what sits underneath them. Revenue of $253.7M in the quarter carried a $24.0M net loss because current income tax expense of $34.8M swamped $4.0M of pre-tax income. The balance sheet has also changed shape fast: long-term debt rose to $293.0M from $143.9M at year-end while cash fell to $88.8M from $102.2M. The new Non-Cannabis segment (Hawthorne plus Bridgewell) added $55.6M of revenue but only a 13% gross margin, well below the 51% cannabis margin, so the mix shift matters for future profitability. Two post-quarter events also landed: a $60.0M Needham Bank loan at 8.50% that refinanced the 15% IFS seller note, and the Fluent acquisition closing November 9 with 6,148,780 shares issued, 3,884,062 of them to CEO-affiliated Chicago Atlantic.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $6.76 on OTC in the Life Sciences sector, with a market capitalization of approximately $351.9M. The 52-week trading range was $6.40 to $21.76. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.